General enquiries

+44 (0) 20 7079 4399

Call HCA from 8am-8pm Mon-Fri and 9am-5pm Sat

HCA Press Releases

Nanoknife: a new technique that will shrink tumours that were previously either difficult to reach or untreatable by surgery

24 April 2012

A PIONEERING new cancer treatment for inoperable tumours in the lungs, kidney, liver, breast, prostate or pancreas is now available at the Princess Grace Hospital.

The technique called NanoKnife destroys soft tissue tumours with an electric current, minimising the risk of damage to nearby organs or blood vessels.

Over the last 20 years, patients with inoperable cancers have been given radiofrequency ablation therapy which heats up the tumour and literally „cooks? it until the cancer cells die.

However, this treatment has its limitations and is not suitable for patients with tumours near major blood vessels.

NanoKnife circumvents these problems by using a 3,000 volt electric current rather than heat to destroy the cancer.

It requires no cuts or incisions. Two disposable fine needles are simply guided through the skin by ultrasound or CT scans to the tumour and then a strong electric current is passed through it for two minutes.

The entire procedure – administering the anaesthetic, guiding the needles in, carrying out the actual treatment and removing the needles – takes around 45 minutes, and is performed under general anaesthetic.

Dr Edward Lean, an interventional radiologist who is carrying out the procedure at the Princess Grace Hospital, London, explains: “This new technology offers the most difficult to treat cancer patients who are not suitable for conventional therapies, an option which could potentially prolong their survival and with good quality of life.

“Instead of killing a tumour by heating it up, a high voltage electric current is passed through it instead.

“This targets the tumour at cell level, perforating the cell membrane and making tiny holes in the cell through which the contents of the cell leaks out and dies.

 “Healthy tissue such as blood vessels, organ lining or the bowel wall is not affected.

 “By perforating the cells, it also potentially allows chemotherapy – generally administered after the operation – to work more effectively on the cancer cells.”

After having NanoKnife, patients are monitored in hospital overnight and are generally allowed to go home the next day. There are no major side-effects.

For most patients with advanced cancer, the procedure will be followed up by a course of chemotherapy.

Michelle Reid, 41, from Glasgow, was the first in Britain to undergo the technique for tumours in her liver which could not be otherwise treated because they were too close to her heart.

Heating up the tumours to the high temperature required by radiofrequency ablation was too risky, and would almost inevitably have caused serious if not fatal damage to her heart.

Michelle has now had two Nanoknife treatments and the tumour next to her heart has shrunk from six centimetres to four centimetres and scans show it is still continuing to shrink.

She said: “It has been amazing to find Dr Leen and get the opportunity to have NanoKnife. It has given me another alternative when my other options were limited.”

ends

This procedure was featured in the Daily Mail on the 15th May 2012. If you would like to view the link online, please go to:

(http://www.dailymail.co.uk/health/article-2124221/3-000-volt-jab-shrunk-inoperable-cancer-half.html )

The Harley Street Clinic
The Lister Hospital
London Bridge Hospital
The Portland Hospital
The Princess Grace Hospital
Wellington hospital
HCA Healthcare UK at The Shard
The Harley Street Clinic Children's Hospital
Harley Street Queens
Harley Street at University College Hospital
The Christie Clinic
LOC
Sarah Cannon Research UK
Blossoms Healthcare
HCA Laboratories
Roodlane Medical
The Wilmslow Hospital
Galen Health Partners
The London Gamma Knife Centre at St Bartholomew's
HCA Healthcare UK

© copyright 2008 - 2016 HCA Healthcare UK.

Registered Name: HCA International Limited; The part of the UK in which it is registered: England and Wales;
Registered Number: 03020522; Registered Office Address: 242 Marylebone Road London NW1 6JL.